Dr. Najjar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2111 Wisconsin Ave NW
Apt 306
Washington, DC 20007Phone+1 202-215-3681Fax+1 412-692-4705
Education & Training
Cleveland Clinic FoundationResidency, Internal Medicine, 2011 - 2014
American University of Beirut Faculty of MedicineClass of 2009
Certifications & Licensure
PA State Medical License 2014 - 2026
OH State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Start of enrollment: 2018 Feb 07
- Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Start of enrollment: 2020 Dec 18
Publications & Presentations
PubMed
- Assessment of adenosinergic activity of small extracellular vesicles in plasma of cancer patients and healthy donors.Chang Sook Hong, Elizabeth V Menchikova, Yana Najjar, Theresa L Whiteside, Edwin K Jackson
Oncoimmunology. 2025-12-01 - Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Tricia R Cottrell, Michael T Lotze, Alaa Ali, Carlo B Bifulco, Christian M Capitini
Journal for Immunotherapy of Cancer. 2025-03-07 - Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.Alexandra G Tompkins, Zane N Gray, Rebekah E Dadey, Serafettin Zenkin, Nasim Batavani
Journal for Immunotherapy of Cancer. 2025-02-12
Press Mentions
Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an Ongoing Phase 2 Trial of Lerapolturev in Anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 CongressOctober 18th, 2022- Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory MelanomaApril 21st, 2021
Analysis Confirms RFS Benefit of Adjuvant High-Dose Interferon Alpha in MelanomaOctober 15th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
